Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
149
datasets available to search
ShareScore release 0.9.0
Dataset results
149 results for “vedolizumab”
A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real Life
ClinicalTrials.gov study NCT03378388. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil
ClinicalTrials.gov study NCT05626088. IPD Sharing: YES. Countries: 1. Publications: 0.
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
ClinicalTrials.gov study NCT06750731. IPD Sharing: YES. Countries: 1. Publications: 0.
OTIS Vedolizumab Pregnancy Exposure Registry
ClinicalTrials.gov study NCT02678052. IPD Sharing: YES. Countries: 1. Publications: 0.
Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
ClinicalTrials.gov study NCT06841705. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World Practice
ClinicalTrials.gov study NCT04890262. IPD Sharing: YES. Countries: 1. Publications: 0.
Residual homing of a α4β7-expressing β1+PI16+ regulatory T cell subset correlates with exposure-efficacy of vedolizumab
GEO Series GSE162624. Homo sapiens. 2 samples. Type: Expression profiling by high throughput sequencing.
Characterization of CD Responders to Vedolizumab
ClinicalTrials.gov study NCT04909359. IPD Sharing: NO. Countries: 1. Publications: 0.
Subcutaneous Interval Lengthening of Vedolizumab for Economic Research
ClinicalTrials.gov study NCT06584162. IPD Sharing: NO. Countries: 1. Publications: 0.
The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis
ClinicalTrials.gov study NCT06609447. IPD Sharing: NO. Countries: 1. Publications: 0.
Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement
ClinicalTrials.gov study NCT06066840. IPD Sharing: NO. Countries: 1. Publications: 0.
VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER)
ClinicalTrials.gov study NCT05158517. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease
ClinicalTrials.gov study NCT07123350. IPD Sharing: NO. Countries: 1. Publications: 0.
the Long-term Retention Rate and Influence Factors of Individualized Treatment of Vedolizumab in Ulcerative Colitis
ClinicalTrials.gov study NCT06856031. IPD Sharing: NO. Countries: 1. Publications: 0.
Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel Disease
ClinicalTrials.gov study NCT04919252. IPD Sharing: NO. Countries: 1. Publications: 0.
Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy
ClinicalTrials.gov study NCT04064697. IPD Sharing: NO. Countries: 1. Publications: 0.
Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.gov study NCT06850727. IPD Sharing: UNDECIDED. Countries: 3. Publications: 0.
Real World Data on Vedolizumab Concentration and Outcomes in Inflammatory Bowel Disease (IBD) Patients Switching From Intravenous (IV) to Subcutaneous (SC) Vedolizumab in University Hospital Center Os
ClinicalTrials.gov study NCT05504915. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concent
ClinicalTrials.gov study NCT06180382. IPD Sharing: NO. Countries: 1. Publications: 0.
Vedolizumab for Immune Mediated Colitis
ClinicalTrials.gov study NCT04797325. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.